HCM — HUTCHMED (China) Share News
0.000.00%
- £1.96bn
- £1.00bn
- $548.51m
Brief: Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination (updated)
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
Hutchmed Initiates Global Trial Of Hmpl: A830
Hutchmed Climbs After On Initiating Hmpl: A830 global trial in solid tumors
Brief: Hutchmed (China) Initiates Global Phase A Trial Of HMPL-A830 In Advanced Solid Tumors
Data to be Presented at ESMO 2026
UK Stocks-Factors to watch on September 3 (updated)
Hutchmed Licenses Kras: EGFR-Antibody to GSK
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug (updated)
HUTCHMED jumps most in near 4 years on GSK licensing deal
UK Stocks-Factors to watch on September 3
HUTCHMED (China) signs exclusive licensing deal with GSK for investigational cancer drug
Brief: Hutchmed Announces Licensing Agreement With GSK For Kras-Egfr-Antibody Conjugate Cancer Therapy
UK Stocks-Factors to watch on September 1 (updated)
AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study (updated)
SANOVO trial demonstrated significant PFS benefit
Brief: HUTCHMED (China) Announces NMPA Conditional Approval For ATLED In China
NMPA Approval for ATLED® (Fanregratinib) for ICC